The company has designed Arc support catheter to improve delivery of its Solitaire stent retriever device and is claimed to provide the fastest route to restoration of blood flow in patients with complex anatomy suffering acute ischemic stroke.
In July this year, the company obtained 510(k) approval from the US Food and Drug Administration (FDA) for Arc catheter series.
The Arc support catheter features a patent-pending manufacturing technology, progressive coil design, allowing the device to deliver better performance.
Medtronic Restorative Therapies Group neurovascular business president Brett Wall said: "The Arc support catheter will complement our Solitaire stent retriever and demonstrates our organization’s focus on the treatment of stroke.
"The device also represents our organization’s ability to continue to deliver innovative technology."
Recently, the company acquired US-based medical device firm Medina Medical, for around $150m, which is involved in commercializing modern treatments for vascular abnormalities of the brain, including cerebral aneurysms.
In August, the firm signed an agreement to acquire another US-based medical device firm Twelve, for around $458m, which is involved in the development of a transcatheter mitral valve replacement (TMVR) device.